Dalia Moged Ahmed

Dr. Dalia Moged Ahmed

University of Saskatchewan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSSaad Shaaban
Saad Shaaban
Amr NegmAmr Negm
Amr Negm
AAAbeer M. Ashmawy
Abeer M. Ashmawy
DADalia Moged Ahmed
Dalia Moged Ahmed
LWLudger A. Wessjohann
Ludger A. Wessjohann

4 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DADalia Moged Ahmed
Dalia Moged Ahmed
JCJeffrey Chen
Jeffrey Chen
DSDavid Sanders
David Sanders
UDP-galactopyranose mutase (UGM) is an essential enzyme involved in the bacterial cell wall synthesis, and is not present in mammalian cells. Thus, UGM from Mycobacterium tuberculosis (Mtb) represents a novel and attractive drug target for developing antituberculosis agents. A pyrazole-based compound, MS208, was previously identified as a mixed inhibitor of MtbUGM which targets an allosteric site. To understand more about the structure activity relationship around the MS208 scaffold as a MtbUGM inhibitor, thirteen pyrazoles and triazole analogues were synthesized and tested against both MtbUGM and Mycobacterium tuberculosis in vitro. While the introduced structural modifications to MS208 did not improve the antituberculosis activity, most of the compounds showed MtbUGM inhibitory activity. Interestingly, the pyrazole derivative DA10 showed a competitive model for MtbUGM inhibition with improved Ki value of 51 ± 4 µM. However, the same compound did not inhibit the growth of Mycobacterium tuberculosis.